Browse by author
Lookup NU author(s): Sally Stapley,
Emeritus Professor Greg RubinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2015 Hamilton et al. Background: This study aimed to answer the question 'for which cancers, in a symptomatic patient, does expediting the diagnosis provide an improvement in mortality and/or morbidity?' Methods: An initial ranking was constructed from previous work identifying 'avoidable deaths' for 21 common cancers in the UK. In a two-round modified Delphi exercise, 22 experts, all experienced across multiple cancers, used an evidence pack summarising recent relevant publications and their own experience to adjust this ranking. Participants also answered on a Likert scale whether they anticipated mortality or morbidity benefits for each cancer from expedited diagnosis. Results: Substantial changes in ranking occurred in the Delphi exercise. Finally, expedited diagnosis was judged to provide the greatest mortality benefit in breast cancer, uterine cancer and melanoma, and least in brain and pancreatic cancers. Three cancers, prostate, brain and pancreas, attracted a median answer of 'disagree' to whether they expected mortality benefits from expedited diagnosis of symptomatic cancer. Conclusions: Our results can guide future research, with emphasis given to studying interventions to improve symptomatic diagnosis of those cancers ranked highly. In contrast, research efforts for cancers with the lowest rankings could be re-directed towards alternative avenues more likely to yield benefit, such as screening or treatment.
Author(s): Hamilton W, Stapley S, Campbell C, Lyratzopoulos G, Rubin G, Neal RD
Publication type: Article
Publication status: Published
Journal: BMC Cancer
Online publication date: 30/10/2015
Acceptance date: 27/10/2015
Date deposited: 14/09/2017
ISSN (electronic): 1471-2407
Publisher: BioMed Central Ltd.
PubMed id: 26514369
Altmetrics provided by Altmetric